Published in J Clin Invest on June 07, 2010
The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20
NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest (2011) 1.58
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 1.52
Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals: the role of SIRT1. Eur J Cancer Prev (2016) 1.39
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov (2014) 1.38
The role of apoptosis-induced proliferation for regeneration and cancer. Cold Spring Harb Perspect Biol (2012) 1.28
Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice. J Clin Invest (2011) 1.20
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov (2013) 1.13
Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08
The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04
Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in mice. PLoS One (2012) 1.03
NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene (2011) 0.97
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res (2014) 0.89
Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease. Parkinsons Dis (2011) 0.89
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88
The canonical NF-κB pathway differentially protects normal and human tumor cells from ROS-induced DNA damage. Cell Signal (2012) 0.87
Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell Melanoma Res (2011) 0.87
Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line. BMC Complement Altern Med (2013) 0.87
NF-κB in cellular senescence and cancer treatment. Mol Cells (2014) 0.85
INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res (2012) 0.85
Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85
Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression. Exp Cell Res (2011) 0.85
Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3. J Invest Dermatol (2015) 0.83
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells. J Biol Chem (2014) 0.79
IKK-β/NF-κB p65 mediates p27(Kip1) protein degradation in arsenite response. Biochem Biophys Res Commun (2014) 0.77
NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation. Oncotarget (2015) 0.77
Ellagic acid inhibits melanoma growth in vitro. Dermatol Reports (2011) 0.75
Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest (2017) 0.75
Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth. Elife (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Cancer-related inflammation. Nature (2008) 34.21
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell (1997) 10.52
Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol (2007) 10.23
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell (1997) 8.74
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 5.87
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature (2003) 5.09
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell (2009) 3.29
Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science (1998) 3.26
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 3.21
BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem (2002) 3.05
At the crossroads of inflammation and cancer. Cell (2004) 2.96
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A (1991) 2.86
The Aurora kinase family in cell division and cancer. Biochim Biophys Acta (2008) 2.84
Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol (2002) 2.81
Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem (1997) 2.55
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell (2002) 2.31
Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. Proc Natl Acad Sci U S A (2000) 2.26
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol (2006) 2.07
Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00
p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell (2003) 1.92
Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res (2001) 1.79
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst (2003) 1.74
Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol (2001) 1.73
Molecular signature of oncogenic ras-induced senescence. Oncogene (2004) 1.60
Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A (2009) 1.45
Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding factor 1 in interleukin (IL)-1beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem (1998) 1.32
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood (2007) 1.29
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29
Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol (2000) 1.26
IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer. EMBO J (2008) 1.24
The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res (2004) 1.19
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood (2004) 1.16
Potential pharmacological control of the NF-κB pathway. Trends Pharmacol Sci (2009) 1.13
Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res (2007) 1.11
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10
INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. Oncogene (1999) 1.09
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther (2007) 1.08
Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology (2009) 1.07
Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma (2008) 1.07
MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. Mdm2 is activated in response to inhibited Akt signaling. J Biol Chem (2006) 1.07
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther (2009) 1.06
Melanocyte stem cell maintenance and hair graying. Cell (2005) 0.99
Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med (2007) 0.97
Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res (2001) 0.97
NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene (2000) 0.93
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet (2005) 0.92
[The alternative NF-kB activation pathway and cancer: friend or foe?]. Med Sci (Paris) (2008) 0.90
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther (2009) 0.85
Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res (1995) 0.84
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol (2007) 0.84
Immunity, inflammation, and cancer. Cell (2010) 28.27
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
The protein kinase IKKepsilon regulates energy balance in obese mice. Cell (2009) 3.93
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol (2006) 2.96
Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 2.89
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 2.74
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56
Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56
Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity (2010) 2.47
JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell (2003) 2.45
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell (2005) 2.38
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc (2007) 2.34
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med (2004) 2.32
Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A (2010) 2.32
p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A (2007) 2.31
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell (2003) 2.23
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature (2004) 2.21
Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res (2002) 2.19
Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A (2004) 2.18
Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum (2009) 2.16